×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
ON DEMAND - Assessing the Adoption of Clinical Trial Results Summary Disclosure to Patients and the Public
Session Chair(s)
Jill McNair, MBA
Key Account Director
Scott Clinical, United States
This session discusses why adoption of plain language summaries remains low and suggests that the absence of clear regulatory requirements and their enforcement are the primary cause.
Learning Objective : Assess the adoption rate of clinical trial results summary disclosure to patients and the public; Review the current lay summary regulatory environment; Analyze current adoption barriers to delivering clinical trial results summaries.
Speaker(s)
Assessing the Adoption Rate of Clinical Trial Results Summary Disclosure
Jill McNair, MBA
Scott Clinical, United States
Key Account Director
Review the Current Lay Summary Environment and Discuss the Implementation Journey
Julie G. Holtzople
AstraZeneca, United States
Senior Director Clinical Transparency and Data Sharing
Have an account?